Evidence map›Paper›PMID 39207706›Full record

ReviewAdvances in neurobiology2024

Infectious Diseases.

Herman Li, Niccolò Terrando, Harris A Gelbard

Abstract readReview
In one paragraph

Review in Advances in neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Herman LiCenter for Neurotherapeutics Discovery, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA.
Niccolò TerrandoCenter for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA.
Harris A GelbardCenter for Neurotherapeutics Discovery, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA. Harris_Gelbard@urmc.rochester.edu.

Funding

VASCULAR FACTORS AND MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASEP01AG007232 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI MAYEUX, RICHARD P · 1989 to 2008
$21.7M
Neurovascular dysfunction in delirium superimposed on dementiaR01AG057525 · NIA · DUKE UNIVERSITY · PI Niccolo Terrando · 2017 to 2026
$6.7M
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).RF1AG079138 · NIA · DUKE UNIVERSITY · PI GELBARD, HARRIS A, TERRANDO, NICCOLO · 2022 to 2025
$3.6M
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1R01MH104147 · NIMH · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A · 2014 to 2018
$3.2M
Immunoprofiling postoperative delirium during aging and neurodegenerationR21AG074232 · NIA · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A, TERRANDO, NICCOLO · 2021 to 2022
$438k
Nanocrystal Quantum Dot Biomimetics of SARS-CoV-2 to Interrogate Neutrophil-Mediated Neuroinflammation at the Blood-Brain BarrierR21NS128502 · NINDS · UNIVERSITY OF ROCHESTER · PI GELBARD, HARRIS A, KRAUSS, TODD D · 2022 to 2022
$424k
NIA NIH HHS P01 AG007232NIA NIH HHS R01 AG057525NIA NIH HHS R21 AG074232NIA NIH HHS RF1 AG079138NIMH NIH HHS R01 MH104147NINDS NIH HHS R21 NS128502
6 · The paper itself

Abstract

Microglia, brain-resident innate immune cells, have been extensively studied in neurodegenerative contexts like Alzheimer's disease. The Coronavirus disease 2019 (COVID-19) pandemic highlighted how peripheral infection and inflammation can be detrimental to the neuroimmune milieu and initiate microgliosis driven by peripheral inflammation. Microglia can remain deleterious to brain health by sustaining inflammation in the central nervous system even after the clearance of the original immunogenic agents. In this chapter, we discuss how pulmonary infection with Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) can lead to neurovascular and neuroimmune inflammation causing the neurological syndrome of post-acute sequelae of COVID-19 (PASC). Further, we incorporate lessons from the Human Immunodeficiency Virus' (HIV's) effects on microglial functioning in the era of combined antiretroviral therapies (cART) that contribute to HIV-1 associated neurocognitive disorders (HAND). Finally, we describe roles for mixed lineage kinase 3 (MLK3) and leucine-rich repeat kinase (LRRK2) as key regulators of multiple inflammatory and apoptotic pathways important to the pathogenesis of PASC and HAND. Inhibition of these pathways provides a therapeutically synergistic method of treating both PASC and HAND.

Indexed as

COVID-19MicrogliaAIDS Dementia ComplexBrainHIV InfectionsHumansPost-Acute COVID-19 SyndromeSARS-CoV-2Coronavirus disease 2019Human immunodeficiency virusHuman immunodeficiency virus-associated neurocognitive disorderInflammationLeucine-rich repeat kinase 2MicrogliaMixed lineage kinase 3Postacute sequelae of coronavirus disease 2019Severe acute respiratory syndrome coronavirus 2

Identifiers

PMID39207706
PMCPMC11556852

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.